Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Inventory

Cash effect of the change in inventory; building inventory consumes cash.

Prothena Corporation plcNASDAQ: PRTA

Inventory · Q1 FY2026 · quarter ended Mar 2026

Inventory outflow grows to $0

Q1 FY2026 inventory was $0, compared with $0 a year earlier. Trailing-twelve-month inventory was $0.

Context

  • Inventory amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Inventory increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly inventory holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Inventory vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so inventory is compared through growth and share of revenue rather than absolute size.
  • Inventory amounts to 0.0% of revenue for PRTA, versus a peer median of 0.4%.
PRTA Competitors
Inventory for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$36.8M USD-67.6%-41.3%0.4%
DNLIDenali Therapeutics Inc.LTM Jun 2026$4.14M USD——114.8%
PRTAProthena Corporation plcLTM Mar 2026$0 USD——0.0%
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Dec 2025CHF 0 CHF——0.0%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
CGTXCognition Therapeutics, Inc.LTM Mar 2026$0 USD———
PMNProMIS Neurosciences, Inc.LTM Jun 2026$0 USD———
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
Peer median (excluding PRTA) —-67.6%-41.3%0.4%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.